$ADMA2025 · v5
ADMA Biologics: 9.4x EV/EBITDA with 18.5x EV/FCF as Cash Conversion Volatility Offsets 27.8% ROIC
Low priority candidate
49Signal score
2025Fiscal year
HealthcareSector
49Low priority candidate
Research PDF
signalshield-ADMA-2025-v5.pdf
⬇ Download full PDFDirect download. Opens in any PDF reader. Public archive report.
This report is provided for informational research support only. It does not constitute investment, financial, or trading advice.
← All research reports